Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Day One Biopharmaceuticals's annualized net income for the quarter that ended in Dec. 2025 was $-85.1 Mil. Day One Biopharmaceuticals's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $427.6 Mil. Therefore, Day One Biopharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -19.90%.
The historical rank and industry rank for Day One Biopharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
DAWN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -62.26 Med: -46.37 Max: -22.91
Current: -23.93
During the past 7 years, Day One Biopharmaceuticals's highest Return-on-Tangible-Equity was -22.91%. The lowest was -62.26%. And the median was -46.37%.
DAWN's Return-on-Tangible-Equity is not ranked
in the Biotechnology industry.
Industry Median: -42.4
vs DAWN: -23.93
Day One Biopharmaceuticals (NAS:DAWN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Day One Biopharmaceuticals Return-on-Tangible-Equity Related Terms
Day One Biopharmaceuticals Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals Return-on-Tangible-Equity Chart
DAWN vs TYRA, DFTX, MLYS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Day One Biopharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -19.90% mean?
Day One Biopharmaceuticals (DAWN) has a Return-on-Tangible-Equity of -19.90% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Day One Biopharmaceuticals and its competitors.
Is Day One Biopharmaceuticals' Return-on-Tangible-Equity too high?
Day One Biopharmaceuticals' current Return-on-Tangible-Equity is -19.90%. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Return-on-Tangible-Equity compare to TYRA and DFTX?
Day One Biopharmaceuticals' Return-on-Tangible-Equity of -19.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Return-on-Tangible-Equity is -19.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Return-on-Tangible-Equity of -19.90%. The current Return-on-Tangible-Equity is -19.90%. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Return-on-Tangible-Equity is -19.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
